[go: up one dir, main page]

CY1110317T1 - Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης - Google Patents

Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης

Info

Publication number
CY1110317T1
CY1110317T1 CY20091100562T CY091100562T CY1110317T1 CY 1110317 T1 CY1110317 T1 CY 1110317T1 CY 20091100562 T CY20091100562 T CY 20091100562T CY 091100562 T CY091100562 T CY 091100562T CY 1110317 T1 CY1110317 T1 CY 1110317T1
Authority
CY
Cyprus
Prior art keywords
substituted
ring
group
atom
pyrimidone derivative
Prior art date
Application number
CY20091100562T
Other languages
English (en)
Inventor
Fumiaki Uehara
Keiichi Aritomo
Aya Shoda
Shinsuke Hiki
Masahiro Okuyama
Yoshihiro Usui
Mitsuru Ooizumi
Kazutoshi Watanabe
Koichi Yamakoshi
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of CY1110317T1 publication Critical patent/CY1110317T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Παράγωγο πυριμιδόνης που παριστάνεται από τον τύπο (I) ή ένα άλας του, ενδιαλύτωμά του ή ένυδρο άλας του το οποίο έχει ανασταλτική δράση κατά της κινάσης 1 πρωτεΐνης τ: στον οποίο το R1 παριστάνει ομάδα C1-C12 αλκυλίου η οποία μπορεί να είναι υποκατεστημένη, το R παριστάνει π.χ. μια ομάδα που παριστάνεται με τον ακόλουθο τύπο (II): στον οποίο τα R2 και R3 παριστάνουν ανεξαρτήτως άτομο υδρογόνου ή ομάδα C1-C8 αλκυλίου, το R4 παριστάνει βενζολικό δακτύλιο ο οποίος μπορεί να είναι υποκατεστημένος, δακτύλιο ναφθαλινίου ο οποίος μπορεί να είναι υποκατεστημένος, δακτύλιο ινδανίου ο οποίος μπορεί να είναι υποκατεστημένος, δακτύλιο τετραϋδροναφθαλινίου ο οποίος μπορεί να είναι υποκατεστημένος, ή προαιρετικώς υποκατεστημένο ετεροκυκλικό δακτύλιο ο οποίος έχει 1 έως 4 ετεροάτομα που επιλέγονται από την ομάδα που αποτελείται από άτομο οξυγόνου, άτομο θείου και άτομο αζώτου, και έχει 5 έως 10 άτομα τα οποία εν συνόλω αποτελούν δακτύλιο.
CY20091100562T 2001-09-21 2009-05-28 Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης CY1110317T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2001331678 2001-09-21
JP2001331675 2001-09-21
JP2001331674 2001-09-21
JP2001331677 2001-09-21
EP02772871A EP1427720B1 (en) 2001-09-21 2002-09-20 3-substituted-4-pyrimidone derivatives

Publications (1)

Publication Number Publication Date
CY1110317T1 true CY1110317T1 (el) 2015-01-14

Family

ID=27482651

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100562T CY1110317T1 (el) 2001-09-21 2009-05-28 Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης

Country Status (24)

Country Link
US (1) US7427615B2 (el)
EP (1) EP1427720B1 (el)
JP (1) JP4347050B2 (el)
KR (1) KR100881821B1 (el)
CN (1) CN100488958C (el)
AT (1) ATE424393T1 (el)
AU (1) AU2002337499B2 (el)
BR (1) BR0212892A (el)
CA (1) CA2460121C (el)
CY (1) CY1110317T1 (el)
DE (1) DE60231414D1 (el)
DK (1) DK1427720T3 (el)
EA (1) EA007576B1 (el)
ES (1) ES2323576T3 (el)
HU (1) HUP0401900A3 (el)
IL (2) IL160700A0 (el)
MX (1) MXPA04002662A (el)
NO (1) NO325781B1 (el)
NZ (1) NZ531636A (el)
PL (1) PL368671A1 (el)
PT (1) PT1427720E (el)
SI (1) SI1427720T1 (el)
TW (1) TWI265164B (el)
WO (1) WO2003037888A1 (el)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
AR043700A1 (es) 2001-09-21 2005-08-10 Mitsubishi Pharma Corp Derivados de 3-substituida-4-pirimidona
US7683069B2 (en) * 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
TWI357408B (en) 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives
ZA200602051B (en) 2003-08-13 2007-10-31 Takeda Pharmaceutical 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
EP1699777B1 (en) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
AR050865A1 (es) * 2004-09-09 2006-11-29 Sanofi Aventis Derivados de 2- morfolino-4-pirimidona
AR051823A1 (es) * 2004-09-29 2007-02-14 Mitsubishi Pharma Corp Derivados de piridinil-pirimidonas
US20090062282A1 (en) * 2004-10-15 2009-03-05 Astrazeneca Ab Substituted Amino-Pyrimidones and Uses Thereof
EP1802587A4 (en) * 2004-10-15 2010-02-17 Astrazeneca Ab SUBSTITUTED AMINO BINDINGS AND THEIR APPLICATIONS
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
PE20070522A1 (es) 2005-09-14 2007-07-11 Takeda Pharmaceutical 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
CA2622642C (en) 2005-09-16 2013-12-31 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
TW200813015A (en) * 2006-03-15 2008-03-16 Mitsubishi Pharma Corp 2-(cyclic amino)-pyrimidone derivatives
KR20090052884A (ko) * 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR064660A1 (es) 2006-12-26 2009-04-15 Mitsubishi Tanabe Pharma Corp Derivados de pirimidinona 6-heterociclica 2-sustituida, medicamentos que los contienen y usos para prevenir y/o tratar enfermedades neurodegenerativas entre otras
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
JP5449147B2 (ja) * 2007-09-14 2014-03-19 サノフイ タウプロテインキナーゼ阻害剤としての、３−メチル−２−（（２ｓ）−２−（４−（３−メチル−１，２，４−オキサジアゾール−５−イル）フェニル）モルホリノ）−６−（ピリミジン−４−イル）ピリミジン−４（３ｈ）−オン
EA201070367A1 (ru) 2007-09-14 2010-08-30 Мицубиси Танабе Фарма Корпорейшн Производное 6-пиримидинилпиримид-4-она
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
WO2011019090A1 (en) 2009-08-13 2011-02-17 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
EP2464639A1 (en) 2009-08-13 2012-06-20 Mitsubishi Tanabe Pharma Corporation Pyrimidone derivatives used as tau protein kinase 1 inhibitors
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
US9745268B2 (en) 2014-09-29 2017-08-29 Chemocentryx, Inc. Processes and intermediates in the preparation of C5aR antagonists
MX2018008624A (es) 2016-01-14 2018-12-10 Chemocentryx Inc Metodo para tratar glomerulopatia c3.

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935631B1 (el) 1970-12-28 1974-09-25
JPS559099B2 (el) 1972-08-07 1980-03-07
JPS4935633A (el) 1972-08-09 1974-04-02
JPS4935632A (el) 1972-08-10 1974-04-02
JPS5124008B2 (el) 1972-08-10 1976-07-21
JPS5271481A (en) 1975-12-10 1977-06-14 Yoshitomi Pharmaceut Ind Ltd Synthesis of pyridylpyrimidines
JPS52139085A (en) * 1976-05-13 1977-11-19 Hokuriku Pharmaceutical 22allylpiperazine derivative and method for its preparation
US4507302A (en) * 1979-03-19 1985-03-26 The Upjohn Company Method for treating arthritis with 6-aryl pyrimidine compounds
US4619933A (en) * 1979-09-28 1986-10-28 The Upjohn Company 6-aryl pyrimidines for treating aplastic anemia
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
EP0354179B1 (de) 1988-07-29 1994-08-17 Ciba-Geigy Ag Thiouracile als Stabilisatoren für chlorhaltige Polymerisate
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． アルツハイマー病の診断および治療用の新規な手段
DE4206145A1 (de) 1992-02-28 1993-09-02 Basf Ag Herbizide n-((pyrimidin-2-yl)aminocarbonyl)benzolfulfonamide
JP3324611B2 (ja) 1992-07-03 2002-09-17 三菱化学株式会社 タウ蛋白質のリン酸化方法
JPH06329551A (ja) 1993-03-22 1994-11-29 Mitsubishi Kasei Corp アルツハイマー病の予防または治療薬およびそのスクリーニング方法
JPH07179442A (ja) * 1993-10-08 1995-07-18 Sagami Chem Res Center ４−イミノオキサゾリジン−２−オン誘導体、それらの製造方法、及びそれらを有効成分とする除草剤
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
US6410729B1 (en) * 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
CN1246858A (zh) 1996-12-05 2000-03-08 安姆根有限公司 取代的嘧啶化合物和它们的应用
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
US6096753A (en) * 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
TWI241298B (en) 1998-09-25 2005-10-11 Mitsubishi Chem Corp Pyrimidone derivatives
RU2277911C2 (ru) * 2000-02-25 2006-06-20 Ф.Хоффманн-Ля Рош Аг Модуляторы аденозиновых рецепторов
AU2001262150A1 (en) 2000-03-23 2001-10-03 Mitsubishi Pharma Corporation 2-(nitrogen-heterocyclic)pyrimidone derivatives
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
AR043700A1 (es) 2001-09-21 2005-08-10 Mitsubishi Pharma Corp Derivados de 3-substituida-4-pirimidona
US7683069B2 (en) 2002-12-16 2010-03-23 Mitsubishi Tanabe Pharma Corporation 3-substituted-4-pyrimidone derivatives
TWI357408B (en) * 2003-03-26 2012-02-01 Mitsubishi Tanabe Pharma Corp 3-substituted-4-pyrimidone derivatives

Also Published As

Publication number Publication date
US20050090490A1 (en) 2005-04-28
DK1427720T3 (da) 2009-05-04
KR20040054689A (ko) 2004-06-25
NO20041600L (no) 2004-06-16
DE60231414D1 (de) 2009-04-16
US7427615B2 (en) 2008-09-23
ATE424393T1 (de) 2009-03-15
CN1556804A (zh) 2004-12-22
HUP0401900A3 (en) 2005-08-29
JP4347050B2 (ja) 2009-10-21
EA200400453A1 (ru) 2004-08-26
WO2003037888A1 (en) 2003-05-08
CA2460121C (en) 2010-11-02
EA007576B1 (ru) 2006-12-29
SI1427720T1 (sl) 2009-08-31
PL368671A1 (en) 2005-04-04
TWI265164B (en) 2006-11-01
AU2002337499B2 (en) 2007-08-23
MXPA04002662A (es) 2004-11-22
BR0212892A (pt) 2004-08-03
ES2323576T3 (es) 2009-07-21
PT1427720E (pt) 2009-04-27
NO325781B1 (no) 2008-07-14
IL160700A (en) 2009-09-22
KR100881821B1 (ko) 2009-02-03
CN100488958C (zh) 2009-05-20
CA2460121A1 (en) 2003-05-08
EP1427720A1 (en) 2004-06-16
NZ531636A (en) 2005-11-25
JP2005510506A (ja) 2005-04-21
HUP0401900A2 (hu) 2004-12-28
IL160700A0 (en) 2004-08-31
EP1427720B1 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
CY1110317T1 (el) Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης
CY1105554T1 (el) Παραγωγα 3-υποκατεστημενης-4-πυριμιδονης
CY1107010T1 (el) Παραγωγο βενζοϋλπυριδινης ´η αλας αυτης, μυκητοκτονο που περιεχει αυτο σαν δραστικο συστατικο, μεθοδος παρασκευης αυτου και ενδιαμεσο για παρασκευη αυτου
BR122017028096B8 (pt) composto, composição farmacêutica, e, uso do composto
NO20023097L (no) Heterocykliske forbindelser med sulfonamidgrupper
CY1107532T1 (el) Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4)
CY1115302T1 (el) Ενωση οξαζολιου και φαρμακευτικη συνθεση
NO983970D0 (no) Tricykliske forbindelser, deres fremstilling og anvendelse
CR9690A (es) 3-acilaminobenzanilidas insecticidas
NO20075312L (no) N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling
NO20060219L (no) Forbindelser
CY1111493T1 (el) Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης
EA200971061A1 (ru) Пиримидоновые соединения гетероариламидов
EA200971062A1 (ru) Производные ариламидпиримидона
EA200500984A1 (ru) Производные 3-замещённого-4-пиримидона
CY1105786T1 (el) Εκδοχα φλαβονων η διαδικασια παρασκευης τους, η εφαρμογη τους ως φαρμακα
CY1108149T1 (el) Αβερμεκτινες και μονοσακχαριτες αβερμεκτινων υποκατασταθεντες στη θεση 4΄ και 4΄΄ εχοντες παρασιτοκτονο δραση
NO20050871L (no) 6-amino-1H-indazol- og 4-aminobenzofuranforbindelser som fosfodiesterase 4-inhibitorer
DE60310609D1 (de) Verfahren zur herstellung von 2-aminomethylpyridin-derivaten
DK1559714T3 (da) Fremgangsmåde til fremstilling af 2-alkyl-3-aminothiophenderivater og 3-aminothiophenderivater
CY1106940T1 (el) Μονοσακχαριδικα παραγωγα της αβερμεκτινης β1
HUP0204560A2 (en) Heterocyclic amide derivatives and pharmaceutical compositions containing them and their use
DE60315626D1 (de) Kondensierte bicyclische pyrimidinderivate
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
BR0110524A (pt) Método para aumentar solubilidade de composto e sistema de solvente